Oruka Therapeutics (ORKA) vs QuidelOrtho (QDEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Oruka Therapeutics (ORKA) has outperformed QuidelOrtho (QDEL) over the past year, gaining 241.6% versus a loss of 55.5%. Over five years, ORKA leads with a +130.8% price change compared with -90.3% for QDEL. Oruka Therapeutics is the larger company by market cap ($5.31 billion vs $877.8 million), about 6.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ORKA | QDEL |
|---|---|---|
| Share price | $80.24 | $12.80 |
| Market cap | $5.31B | $877.77M |
| 1-day change | +3.82% | +3.14% |
| YTD return | +154.97% | -56.55% |
| 1-year return | +241.64% | -55.46% |
| 5-year return | +130.82% | -90.32% |
| Forward P/E | — | 8.88 |
| EPS (TTM) | $-2.04 | $-15.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-105.43M | — |
| 52-week high | $115.52 | $35.58 |
| 52-week low | $24.31 | $9.92 |
| Distance from 52-week high | -30.54% | -64.02% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +93.18% | +14.61% |
| Average volume | 896.59K | 1.51M |
| Shares outstanding | 66.21M | 68.58M |
| Employees | 68 | 6,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Oruka Therapeutics is about 6.1 times larger than QuidelOrtho by market value ($5.31B vs $877.77M).
- ORKA has outperformed QDEL by 297.1 percentage points over the past year.
About Oruka Therapeutics
ORKA stock →Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 68 employees
About QuidelOrtho
QDEL stock →QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 6,500 employees
ORKA vs QDEL FAQ
Which is bigger, Oruka Therapeutics or QuidelOrtho?
Oruka Therapeutics (ORKA) is larger, with a market capitalization of $5.31B compared with $877.77M for QuidelOrtho (QDEL).
Which stock has performed better over the past year, ORKA or QDEL?
ORKA returned +241.64% over the past 12 months, compared with -55.46% for QDEL (price return, excluding dividends). Past performance does not predict future results.
Are Oruka Therapeutics and QuidelOrtho in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.